Business Context and Reporting Period
Company: Castle Biosciences, Inc. (CSTL)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2025
Reporting Period: Preliminary results for the fourth quarter of 2024 and the full year ended December 31, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that preliminary performance results were announced via a press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2), which are incorporated by reference but not detailed within the body of this specific document.
Material Changes
No specific material changes or comparative financial data are disclosed in the text of this filing. The document references the issuance of preliminary results but does not quantify changes versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release and slide presentation regarding preliminary 2024 performance.
Legal Disclaimer: The information contained in this 8-K and its exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures for Q4 and FY 2024.
- Examine Exhibit 99.2 (Slide Presentation) for detailed operational metrics and forward-looking guidance.
- Verify the Company's liquidity position and debt obligations in the full financial statements referenced in the press release.
- Confirm any updates to the Company's 2025 financial outlook provided in the management presentation.